Biotech Takeover Targets 2025. But there are signs of a rebound, with a flurry of dealmaking to close out 2023. Likely targets include companies focused on precision oncology, cell and gene therapies, mrna and immunology, analysts say.
But there are signs of a rebound, with a flurry of dealmaking to close out 2023. Only 19 biotechs went public last year, down slightly from 2022.
These May Be The Next Acquisition Targets.
Big pharma will have $500 billion to spend in 2022 and is hungry for m&a.
Cancer, Rare Disease, And To A Lesser Extent Central Nervous System Players Are Targets That Match Up Most Closely With Prospective Buyers.
Biotech m&a activity surged at the end of 2023, which helped small biotech sector surge.
Biotech Takeover Targets 2025 Images References :
Click Here To Read What Investors Need To Know.
Already more than half a dozen biotech companies have announced layoffs, and venture investors have signaled changes in how they plan to build new startups.
Biotech Is Ripe For M&Amp;A.
Big pharma will have $500 billion to spend in 2022 and is hungry for m&a.